As of 19 Nov 2026, NexThera has raised $16.7M across 1 verified round on record; latest: USD 16.7 million (22 billion won) Series B led by Woori Venture Partners, announced 28 Sep 2026.
A biotech venture developing therapies for ocular diseases
nexthera.orgHaeundae-gu, Busan, South KoreaBiotechFounded 2020
5 sources · checked 33 times, last 6d ago
Source 4 dates the round to 2026-09-29, but the specific WOWTALE article states it was announced on September 28; the specific article is preferred.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B Series B funding round | $16.7M $29.6M to date | 2026-09-28 | Woori Venture Partners | No recent discussion |
5 sources · checked 33 times, last 6d ago [ VERIFIED · CORRECTED ] read against 4 of 5 sources Source 4 dates the round to 2026-09-29, but the specific WOWTALE article states it was announced on September 28; the specific article is preferred. | ||||
1 person on 2 outlets
Found on X with Firecrawl search
NexThera is a biotech venture that uses recombinant-protein and peptide platforms to develop non-invasive eye-drop therapies for retinal diseases such as wet age-related macular degeneration and diabetic retinopathy, as well as biobetters.
NexThera is pursuing a non-invasive eye-drop alternative to repeated intravitreal injections for wet AMD, where current treatment can be uncomfortable and carries risks including infection, bleeding, and retinal detachment. Its latest reported financing is intended to complete the U.S. NT-101 trial and prepare for an IPO, while the first part of that trial reported a mean 6.2-letter visual-acuity improvement in the high-dose group, making the clinical readout and commercialization bet consequential.
Checked against 8 sources on Sep 29
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Strategic investment | KRW 3.0 billion | 2024-03 | not stated | |
| Series A+ bridge | KRW 5.5 billion | 2023-12 | Solidus Investment, Fast Ventures | |
| Series A | KRW 7.0 billion | 2021-10-13 | not stated | |
Also named as backers in company research: BNK VC, Platinum Technology Investment, Korea Technology Finance Corporation (Kibo), DAOL Investment, KB Securities, Solidus Investment, Fast Ventures, KCRN Research, EyeGene, Inc., BMI Korea Co., Ltd., Muir Woods Ventures, Linea Investment, Ministry of SMEs and Startups, Ministry of Science and ICT, Busan Economic Promotion Agency, TECH Valley, TIPS Program (Accelerator Investment-Driven Tech Incubator Program for Startup), Korea Institute of Startup & Entrepreneurship Development, Korea Planning & Evaluation of Industrial Technology, Korea Drug Development Fund, Startup Leap Package, Scale-up TIPS Program, INNOPOLIS Grants for Public Technology Commercialization, National New Drug Development Project, Frontier Venture by TECH Valley